{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:22:26Z","timestamp":1789611746264,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40273-021-01121-7","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T20:03:06Z","timestamp":1643832186000},"page":"519-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-4552","authenticated-orcid":false,"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Haiderali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Frederickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"issue":"3","key":"1121_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1121_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412\u201324.","journal-title":"World J Clin Oncol."},{"issue":"3","key":"1121_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"20","key":"1121_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"key":"1121_CR5","unstructured":"Merck. FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple\u2011Negative Breast Cancer Whose Tumors Express PD-L1 (CPS \u226510). Merck. Available at: https:\/\/www.merck.com\/news\/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-patients-with-locally-recurrent-unresectable-or-metastatic-triple%e2%80%91negative-breast-cancer-whose\/. Published 2020. Accessed 19 Nov 2021."},{"key":"1121_CR6","unstructured":"Merck. FDA Approves KEYTRUDA\u00ae (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Merck. Available at: https:\/\/www.merck.com\/news\/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued\/. Published 2021. Accessed 19 Nov 2021."},{"key":"1121_CR7","unstructured":"Merck. European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC). Merck. Available at: https:\/\/www.merck.com\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast\/. Accessed 19 Nov 2021."},{"key":"1121_CR8","unstructured":"Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. National Comprehensive Cancer Network. Available at: www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Published 2021. Accessed 21 June 2021."},{"issue":"12","key":"1121_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"8","key":"1121_CR10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol"},{"key":"1121_CR11","doi-asserted-by":"crossref","unstructured":"Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat. 2012;134(2): 815-822.","DOI":"10.1007\/s10549-012-2097-2"},{"issue":"6","key":"1121_CR12","first-page":"405","volume":"37","author":"TS Foster","year":"2011","unstructured":"Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev. 2011;37(6):405\u201315.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"1121_CR13","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1158\/1055-9965.EPI-11-0650","volume":"20","author":"KR Yabroff","year":"2011","unstructured":"Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomark Prev. 2011;20(10):2006\u201314.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1121_CR14","volume-title":"The global economic cost of cancer","author":"R John","year":"2010","unstructured":"John R, Ross H. The global economic cost of cancer. American Cancer Society; 2010."},{"issue":"6","key":"1121_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00019053-200321060-00003","volume":"21","author":"D Radice","year":"2003","unstructured":"Radice D, Redaelli A. Breast Cancer Management. Pharmacoeconomics. 2003;21(6):383\u201396.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1121_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3896","volume":"15","author":"EC Dietze","year":"2015","unstructured":"Dietze EC, Sistrunk C, Miranda-Carboni G, O\u2019Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15(4):248\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1121_CR17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/jnci\/djn175","volume":"100","author":"JL Warren","year":"2008","unstructured":"Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888\u201397.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1121_CR18","doi-asserted-by":"publisher","first-page":"A742","DOI":"10.1016\/j.jval.2016.09.2263","volume":"19","author":"J Zhuo","year":"2016","unstructured":"Zhuo J, Wu E, Dasbach EJ, Pellissier J. PCN190 Cancer Associated Medical Spending: US National Data Between 2000 and 2013. Value Health. 2016;19(7):A742\u20133.","journal-title":"Value Health."},{"issue":"2","key":"1121_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10549-007-9650-4","volume":"109","author":"JJ Barron","year":"2008","unstructured":"Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109(2):367\u201377.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1121_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1524-4733.2000.31003.x","volume":"3","author":"N Berkowitz","year":"2000","unstructured":"Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3(1):23\u201330.","journal-title":"Value Health."},{"issue":"2","key":"1121_CR21","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/curroncol28020117","volume":"28","author":"N Iragorri","year":"2021","unstructured":"Iragorri N, de Oliveira C, Fitzgerald N, Essue B. The out-of-pocket cost burden of cancer care\u2014a systematic literature review. Curr Oncol. 2021;28(2):1216\u201348.","journal-title":"Curr Oncol"},{"issue":"2","key":"1121_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.amepre.2015.10.006","volume":"50","author":"DU Ekwueme","year":"2016","unstructured":"Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP Jr. Productivity costs associated with breast cancer among survivors aged 18\u201344 years. Am J Prev Med. 2016;50(2):286\u201394.","journal-title":"Am J Prev Med"},{"key":"1121_CR23","doi-asserted-by":"crossref","unstructured":"Holmstrom SHN, Dam S, Aballea S, Oestreicher N, Evans C, Novak A, Dydo M. Elicitation of health-related quality-of-life concepts associated with triple-negative breast cancer. Value in Health. 2015;18(3): 212.","DOI":"10.1016\/j.jval.2015.03.1226"},{"issue":"3","key":"1121_CR24","doi-asserted-by":"publisher","first-page":"A212","DOI":"10.1016\/j.jval.2015.03.1226","volume":"18","author":"S Holmstrom","year":"2015","unstructured":"Holmstrom S, Hawken NA, Dam S, et al. Elicitation of health-related quality-of-life concepts associated with triple-negative breast cancer. Value Health. 2015;18(3):A212.","journal-title":"Value Health."},{"issue":"1","key":"1121_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12955-020-01591-x","volume":"18","author":"P Mokhatri-Hesari","year":"2020","unstructured":"Mokhatri-Hesari P, Montazeri A. Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes. 2020;18(1):338.","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"1121_CR26","first-page":"615","volume":"75","author":"SJ Swiger K","year":"2020","unstructured":"Swiger K SJ, Guglielmino J. Emotional\/psychological characteristics of women with triple-negative breast cancer: Do socioeconomic, demographic, and provider variables impact emotional change from diagnosis to post-treatment? Cancer Res. 75(9):615.","journal-title":"Cancer Res"},{"issue":"2","key":"1121_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-017-4173-0","volume":"163","author":"ST Vadaparampil","year":"2017","unstructured":"Vadaparampil ST, Christie J, Donovan KA, et al. Health-related quality of life in black breast cancer survivors with and without triple negative breast cancer (TNBC). Breast Cancer Res Treat. 2017;163(2):331\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"9 Suppl","key":"1121_CR28","doi-asserted-by":"crossref","first-page":"P5-17-06","DOI":"10.1158\/1538-7445.SABCS14-P5-17-06","volume":"75","author":"KD Swiger","year":"2015","unstructured":"Swiger KD, Sendecki JA, Guglielmino JE, et al. Abstract P5\u201317-06: Emotional\/psychological characteristics of women with triple-negative breast cancer: Do socioeconomic, demographic, and provider variables impact emotional change from diagnosis to post-treatment? Cancer Res. 2015;75(9 Suppl):P5-17\u201306.","journal-title":"Cancer Res"},{"issue":"1","key":"1121_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2217\/cer-2017-0027","volume":"7","author":"M Parisi","year":"2018","unstructured":"Parisi M, Pelletier C, Cherepanov D, Broder MS. Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review. J Comp Effect Res. 2018;7(1):67\u201383.","journal-title":"J Comp Effect Res."},{"key":"1121_CR30","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"1121_CR31","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1121_CR32","unstructured":"Wells GS, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 1 Oct 2016."},{"issue":"9","key":"1121_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","volume":"22","author":"HC Turner","year":"2019","unstructured":"Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019;22(9):1026\u201332.","journal-title":"Value Health."},{"key":"1121_CR34","unstructured":"Medical consumer price index. US Bureau of Labor Statistics. Available at: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm. Accessed 5 Jul 2021."},{"issue":"9","key":"1121_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2217\/fon-2018-0407","volume":"15","author":"A Aly","year":"2019","unstructured":"Aly A, Shah R, Hill K, Botteman MF. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer. Future Oncol. 2019;15(9):1007\u201320.","journal-title":"Future Oncol"},{"issue":"3","key":"1121_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1185\/03007995.2011.628649","volume":"28","author":"O Ba\u015fer","year":"2012","unstructured":"Ba\u015fer O, Wei W, Henk HJ, Teitelbaum A, Xie L. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. Curr Med Res Opin. 2012;28(3):419\u201328.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1121_CR37","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.ehrm.2012.03.001","volume":"3","author":"O Ba\u015fer","year":"2012","unstructured":"Ba\u015fer O, Wei W, Henk HJ, Teitelbaum A, Xie L. Burden of early-stage triple-negative breast cancer in a US managed care plan. Health Outcomes Res Med. 2012;3(2):e57\u201365.","journal-title":"Health Outcomes Res Med."},{"key":"1121_CR38","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.ctarc.2019.100121","volume":"19","author":"AC Houts","year":"2019","unstructured":"Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings. Cancer Treat Res Commun. 2019;19:100121.","journal-title":"Cancer Treat Res Commun."},{"issue":"10","key":"1121_CR39","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/cncr.31299","volume":"124","author":"KL Schwartz","year":"2018","unstructured":"Schwartz KL, Simon MS, Bylsma LC, et al. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States. Cancer. 2018;124(10):2104\u201314.","journal-title":"Cancer"},{"issue":"9","key":"1121_CR40","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/fon-2020-0996","volume":"17","author":"J Sieluk","year":"2020","unstructured":"Sieluk J, Haiderali A, Huang M, Yang L, Hirshfield KM. Early triple-negative breast cancer in women aged \u226565: retrospective study of outcomes, resource use and costs, 2010\u20132016. Future Oncol. 2020;17(9):1039\u201354.","journal-title":"Future Oncol"},{"issue":"20","key":"1121_CR41","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.2217\/fon-2021-0019","volume":"17","author":"J Sieluk","year":"2021","unstructured":"Sieluk J, Yang L, Haiderali A, Huang M, Hirshfield KM. Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age \u226565 years. Future Oncol. 2021;17(20):2581\u201392.","journal-title":"Future Oncol"},{"issue":"20","key":"1121_CR42","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1002\/cam4.3038","volume":"9","author":"C Brezden-Masley","year":"2020","unstructured":"Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer. Cancer Med. 2020;9(20):7548\u201357.","journal-title":"Cancer Med"},{"key":"1121_CR43","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jval.2021.04.330","volume":"24","author":"J Sieluk","year":"2021","unstructured":"Sieluk J, Haiderali A, Huang M, et al. PCN240 Healthcare Resource Utilization Associated With Disease Recurrence Among Surgically-Treated Patients With Triple-Negative Breast Cancer. Value in Health. 2021;24:S65.","journal-title":"Value in Health."},{"key":"1121_CR44","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.annonc.2020.03.043","volume":"31","author":"W Rhodes","year":"2020","unstructured":"Rhodes W, Gautam S, Haiderali A, et al. 104P Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC). Ann Oncol. 2020;31:S51.","journal-title":"Ann Oncol"},{"key":"1121_CR45","doi-asserted-by":"crossref","unstructured":"De las Heras BB, Cortes Ramon y Cajal J, Galve Calvo E, et al. The economic burden of metastatic breast cancer in Spain. Eur J Hosp Pharm. 2020; 27(1):19\u201324.","DOI":"10.1136\/ejhpharm-2017-001453"},{"issue":"6","key":"1121_CR46","doi-asserted-by":"publisher","first-page":"e000984","DOI":"10.1136\/esmoopen-2020-000984","volume":"5","author":"M Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o M, Morais S, Lopes-Concei\u00e7\u00e3o L, Fontes F, Ara\u00fajo N, Dias T, et al. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open. 2020;5(6):e000984.","journal-title":"ESMO Open."},{"issue":"1","key":"1121_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499583","volume":"97","author":"B Mery","year":"2019","unstructured":"Mery B, Rowinski E, Vallard A, et al. Advocacy for a new oncology research paradigm: the model of bevacizumab in triple-negative breast cancer in a French Cohort Study. Oncology. 2019;97(1):1\u20136.","journal-title":"Oncology"},{"issue":"7","key":"1121_CR48","doi-asserted-by":"publisher","first-page":"e035389","DOI":"10.1136\/bmjopen-2019-035389","volume":"10","author":"E Roman","year":"2020","unstructured":"Roman E, Cardoen B, Decloedt J, Roodhooft F. Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients. BMJ Open. 2020;10(7):e035389.","journal-title":"BMJ Open"},{"issue":"2","key":"1121_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/cer-2020-0213","volume":"10","author":"KE Skinner","year":"2020","unstructured":"Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. J Comp Effect Res. 2020;10(2):109\u201318.","journal-title":"J Comp Effect Res."},{"key":"1121_CR50","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jval.2020.04.1777","volume":"23","author":"RC Parikh","year":"2020","unstructured":"Parikh RC, Niyazov A, Esterberg E, et al. Real-world patient demographics, treatment patterns and healthcare resource utilization (HRU) among Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer (ABC) patients with BRCA1\/2 Mutations (BRCA1\/2MUT). Value Health. 2020;23:S79.","journal-title":"Value Health."},{"issue":"2","key":"1121_CR51","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jgo.2020.09.004","volume":"12","author":"A Valachis","year":"2021","unstructured":"Valachis A, Nystr\u00f6m P, Fredriksson I, Wennstig AK, Ahlgren J. Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer. J Geriatr Oncol. 2021;12(2):212\u20138.","journal-title":"J Geriatr Oncol."},{"issue":"4 Suppl","key":"1121_CR52","doi-asserted-by":"crossref","first-page":"P2-08-09","DOI":"10.1158\/1538-7445.SABCS19-P2-08-09","volume":"80","author":"A Tabah","year":"2020","unstructured":"Tabah A, Copher R, Huggar D, Tian M, Mougalian SS. Abstract P2\u201308-09: Treatment patterns and costs of metastatic triple negative breast cancer (mTNBC) in US women: a retrospective cohort study of first-line chemotherapy. Cancer Res. 2020;80(4 Suppl):P2-08\u20139.","journal-title":"Cancer Res"},{"key":"1121_CR53","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jval.2021.04.338","volume":"24","author":"J Sieluk","year":"2021","unstructured":"Sieluk J, Haiderali A, Huang M, et al. PCN248 productivity costs associated with disease recurrence among surgically-treated patients with triple-negative breast cancer. Value in Health. 2021;24:S66.","journal-title":"Value in Health."},{"issue":"5","key":"1121_CR54","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","volume":"31","author":"S Adams","year":"2020","unstructured":"Adams S, Di\u00e9ras V, Barrios CH, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582\u20139.","journal-title":"Ann Oncol"},{"key":"1121_CR55","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jval.2020.04.1771","volume":"23","author":"M Huang","year":"2020","unstructured":"Huang M, Haiderali A, Hu P, Mejia J. PCN308 health utility in patients with previously treated metastatic TNBC. Value in Health. 2020;23:S78.","journal-title":"Value in Health."},{"issue":"8","key":"1121_CR56","doi-asserted-by":"publisher","first-page":"VIII91","DOI":"10.1093\/annonc\/mdy272.284","volume":"29","author":"H Rugo","year":"2018","unstructured":"Rugo H, Quek R, Ettl J, et al. 292O Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1\/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician\u2019s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation. Ann Oncol. 2018;29(8):VIII91.","journal-title":"Ann Oncol"},{"key":"1121_CR57","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.annonc.2020.03.242","volume":"31","author":"P Schmid","year":"2020","unstructured":"Schmid P, Haiderali A, Mejia J, et al. 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer. Ann Oncol. 2020;31:S65\u20136.","journal-title":"Ann Oncol"},{"issue":"10","key":"1121_CR58","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1007\/s00520-015-2667-z","volume":"23","author":"AK Swisher","year":"2015","unstructured":"Swisher AK, Abraham J, Bonner D, Gilleland D, Hobbs G, Kurian S, et al. Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile. Support Care Cancer. 2015;23(10):2995\u20133003.","journal-title":"Support Care Cancer"},{"issue":"3","key":"1121_CR59","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10549-014-3039-y","volume":"146","author":"C Anders","year":"2014","unstructured":"Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, et al. TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014;146(3):557\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"1121_CR60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1200\/jco.2013.31.15_suppl.515","volume":"31","author":"CK Anders","year":"2013","unstructured":"Anders CK, Deal AM, Abramson VG, Liu MC, Storniolo AM, Carpenter JT, et al. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). J Clin Oncol Conf. 2013;31(15):515.","journal-title":"J Clin Oncol Conf"},{"key":"1121_CR61","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.ejon.2020.101771","volume":"46","author":"A Shen","year":"2020","unstructured":"Shen A, Qiang W, Wang Y, Chen Y. Quality of life among breast cancer survivors with triple negative breast cancer \u2013 role of hope, self-efficacy and social support. Eur J Oncol Nurs. 2020;46:1771.","journal-title":"Eur J Oncol Nurs"},{"key":"1121_CR62","doi-asserted-by":"crossref","unstructured":"Vadaparampil ST, Christie J, Donovan K, Kim J, Augusto B, Holt C, et al. Health-related quality of life in black breast cancer patients with Triple Negative Breast Cancer (TNBC). In: Cancer Epidemiology Biomarkers and Prevention Conference: 9th AACR Conference on the Science of Cancer Health Disparities in Racial\/Ethnic Minorities and the Medically Underserved United States. 2017;26(2):B26.","DOI":"10.1158\/1538-7755.DISP16-B26"},{"issue":"2","key":"1121_CR63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-017-4173-0","volume":"163","author":"ST Vadaparampil","year":"2017","unstructured":"Vadaparampil ST, Christie J, Donovan KA, Kim J, Augusto B, Kasting M, et al. Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2017;163(2):331\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1121_CR64","first-page":"149","volume":"60","author":"C Mocerino","year":"2012","unstructured":"Mocerino C, Letizia A, Taddeo M, Gambardella A. Tolerability of bevacizumab in elderly patients with \u201ctriple-negative\u201d metastatic breast cancer. G Gerontol. 2012;60(3):149\u201353.","journal-title":"G Gerontol"},{"issue":"5","key":"1121_CR65","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1121_CR66","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756\u201368.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1121_CR67","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","volume":"44","author":"K Cocks","year":"2008","unstructured":"Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44(13):1793\u20138.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1121_CR68","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974\u201386.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1121_CR69","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","volume":"57","author":"DT Eton","year":"2004","unstructured":"Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57(9):898\u2013910.","journal-title":"J Clin Epidemiol"},{"issue":"4 Suppl","key":"1121_CR70","doi-asserted-by":"crossref","first-page":"P5-12-09","DOI":"10.1158\/1538-7445.SABCS19-P5-12-09","volume":"80","author":"TA Traina","year":"2020","unstructured":"Traina TA, Jones LW, Blinder V, et al. Abstract P5\u201312-09: Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer. Cancer Res. 2020;80(4 Suppl):P5-12\u201309.","journal-title":"Cancer Res"},{"issue":"5","key":"1121_CR71","first-page":"360","volume":"20","author":"FM Naidoo S","year":"2017","unstructured":"Naidoo S FM, Paly VF, Hansen R, Sidhu MK, Smith I. Targeted literature review of advanced\/metastatic triple-negative breast cancer burden of illness. Value Health. 2017;20(5):360.","journal-title":"Value Health."},{"key":"1121_CR72","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jval.2019.04.182","volume":"22","author":"A Fu","year":"2019","unstructured":"Fu A, Breznen B, Fazeli MS, Hux M, Kumar N, Davis C. PCN58 humanistic and economic burdens of triple-negative breast cancer: a literature review. Value Health. 2019;22:S67.","journal-title":"Value Health."},{"key":"1121_CR73","doi-asserted-by":"publisher","first-page":"S527","DOI":"10.1016\/j.jval.2019.09.660","volume":"22","author":"A Frederickson","year":"2019","unstructured":"Frederickson A, Haiderali A, Zhang J, Chang A, Huang M. PCN468 systematic review of utility estimates in triple-negative breast cancer patients. Value Health. 2019;22:S527\u20138.","journal-title":"Value Health."},{"key":"1121_CR74","doi-asserted-by":"publisher","first-page":"S461","DOI":"10.1016\/j.jval.2019.09.328","volume":"22","author":"A Frederickson","year":"2019","unstructured":"Frederickson A, Haiderali A, Zhang J, Chang A, Huang M. PCN132 systematic review of economic burden in triple-negative breast cancer patients. Value Health. 2019;22:S461.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01121-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01121-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01121-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T13:00:36Z","timestamp":1674651636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01121-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01121-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"28 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Merck & Co., Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Min Huang and Amin Haiderali are employees of Merck & Co. Inc., the sponsor of this study and corresponding manuscript. Grace E. Fox and Andrew Frederickson are employees of PRECISIONheor, a healthcare research consultancy that has received funding from Merck and Co., Inc. Javier Cortes provides advisory and consultancy services to Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, and Gilead. Peter A. Fasching reports personal fees from Novartis Pfizer, Daiichi-Sankyo, AstraZeneca, Eisai, Merck Sharp & Dohme, Lilly Pierre Fabre, SeaGen, Roche, Hexal, and Agendia, and grants from Biontech and Cepheid. Joyce O\u2019Shaughnessy receives consulting fees and\/or honorarium from AbbVie Inc., Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Takeda, and Synthon.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"All included publications were obtained through publicly available sources. All data generated or analyzed during this study are included in this published article or the electronic supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study design and data analyses, interpretation of the results, and development and writing of the draft manuscript, and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}